Pharmaceutical companies spend millions each year purchasing commercial marketed products for use in clinical studies. Supply chain intermediaries can decrease security, introduce delays, and cannot provide access to key drug documentation. With a decreasing supply, increasing demand, and cost of these “Comparators”, there is opportunity for a counterfeit issue to arise.
To address this need, TransCelerate’s Comparator Network provides an established channel through which participating Member Companies can reliably and rapidly source quality comparator products from each other for use in clinical trials.
The Comparator Network has allowed Member Companies to reliably and rapidly source quality products for use in clinical trials, ultimately enabling accelerated trial timelines and enhanced patient safety.
The success of the Comparator Network has laid the foundation for the sharing of materials beyond commercial product such as bulk drug product, and blinded active and placebo. These newly expanded exchanges reduce clinical trial costs and complexity, decrease the risk of unblinding, and improve patient safety by ensuring that comparators are used in their intended presentations.
The Comparator Network also helps enhance patient safety due to known source of materials and comparator drug documentation. It limits the chance for counterfeits to enter the investigational supply chain and allows for the continuity of drug supply for products used in studies.
- Enhanced patient safety due to known source of materials and comparator drug documentation
- Limited chance for counterfeits to enter the investigational supply chain
- Allows for the continuity of drug supply for products used in studies
Access to the Comparator Network is provided for TransCelerate Member Companies only.